Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
silybin + carvedilol
- Development stage
- Unknown
- Lead developer
- Tasly Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TSL2402 (also known as CMI2402) is an oral fixed-dose combination tablet containing silybin and carvedilol, developed by Tasly Pharmaceutical Group in collaboration with China Pharmaceutical University. It is designed as a Class 2.3 Modified New Combination Pharmaceutical for the treatment of primary biliary cholangitis (PBC) in patients with Scheuer stage S2 or higher liver fibrosis who can tolerate ursodeoxycholic acid (UDCA) baseline treatment. Silybin, a natural hepatoprotective compound, and carvedilol, a non-selective beta-blocker, act synergistically to inhibit hepatic stellate cell (HSC) activation and reduce excessive collagen deposition. Mechanistically, the combination targets the Wnt/β-catenin signaling pathway, specifically down-regulating the Wnt ligand Wnt4, to alleviate liver fibrosis. TSL2402 received clinical trial approval from China's National Medical Products Administration (NMPA) in August 2026.
- Other names
- TSL 2402TSL2402TSL-2402水飞蓟宾卡维地洛片
02
Targets
ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)ADRB1 (β1)ADRB2 (β2)
Beyond the preview
Go deeper on silybin + carvedilol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on silybin + carvedilol.